Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Bruce Goldsmith
|
| gptkbp:collaboratesWith |
gptkb:University_of_Pennsylvania
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
gene therapies
rare monogenic central nervous system diseases |
| gptkbp:founded |
2017
|
| gptkbp:founder |
James M. Wilson
|
| gptkbp:headquarters_location |
gptkb:Philadelphia,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Passage Bio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:numberOfEmployees |
approximately 50-100 (as of 2023)
|
| gptkbp:platform |
AAV gene therapy
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
PASG
|
| gptkbp:therapeuticArea |
gptkb:GM1_gangliosidosis
frontotemporal dementia Krabbe disease |
| gptkbp:website |
https://www.passagebio.com/
|
| gptkbp:bfsParent |
gptkb:Stephen_Squinto
|
| gptkbp:bfsLayer |
7
|